Ambuja Cements Limited (AMBUJACEM) — Announcement | 28 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Ambuja Cements reports Q1 FY'27 results with 8% revenue growth and ₹206 PMT cost reduction target.
🔄 What Changed
19% YoY EBITDA growth and 13% EBITDA/PMT growth versus prior year
🔮 What's Next
Target cost reduction of ₹250 PMT in FY'27; capacity expansion to 119 MTPA by FY'27
💡 Investor Takeaway
Shareholders benefit from accelerating cost efficiency and ESG-aligned growth driving margins.
⚠️ Risks
Higher packing material costs due to West Asia crisis

Ambuja Cements presented its Q1 FY'27 investor deck on July 28, 2026, highlighting strong operational momentum and sustainability leadership. Revenue grew 8% YoY to ₹9,500 Cr with EBITDA up 19% to ₹1,589 Cr, driven by cost discipline and green initiatives. The company achieved ₹206 PMT sequential cost reduction while advancing its ₹250 PMT target, with blended cement at 65.8% and 85% green power usage. Sustainalytics rated it #8/#9 for ESG, reflecting robust climate and circular economy metrics. Capacity expansion to 119 MTPA by FY'27 is underway, supported by premium cement (34% of trade sales) and trade sales at 78% of total volume. The presentation underscores strategic focus on cost leadership, ESG integration, and capacity growth to capture market share in a competitive infrastructure cycle.

📄 View Original Announcement (PDF)

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AMBUJACEM — Free

Free account · 2 AI queries/day